Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6902835 | 0.84 | SMN1; SMN2 (0.50) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL6909883 | 0.84 | SMN1; SMN2 (0.50) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL6909766 | 0.84 | SMN1; SMN2 (0.50) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL6908199 | 0.81 | SMN1; SMN2 (0.46) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL6904723 | 0.81 | SMN1; SMN2 (0.54) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL6906075 | 0.81 | SMN1; SMN2 (0.54) | LMNAUSP2SMN1; SMN2HPGDTP53 | |
| SCHEMBL6907247 | 0.80 | HPGD (0.53) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL6906554 | 0.79 | SMN1; SMN2 (0.52) | LMNAUSP2SMN1; SMN2HPGDTP53 | |
| SCHEMBL6910302 | 0.77 | SMN1; SMN2 (0.49) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL6910243 | 0.77 | SMN1; SMN2 (0.49) | LMNAPOLBUSP2SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747061-B2 | ADMINISTERING AN ANTIPROLIFERATIVE AGENT IN COMBINATION WITH A POTENTIATING EFFECTIVE AMOUNT OF A N- SUBSTITUTED DITHIOCARBAMATE ESTER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ATHEROGENICS, INC. | 2004-06-08 | — | — | US | claimed |
| US-20030176496-A1 | Administering an antiproliferative agent in combination with a potentiating effective amount of a N- substituted dithiocarbamate ester or a pharmaceutically acceptable salt thereof | ATHEROGENICS, INC. (US) | 2003-09-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176496-A1 | Administering an antiproliferative agent in combination with a potentiating effective amount of a N- substituted dithiocarbamate ester or a pharmaceutically acceptable salt thereof | VCAM1, MKI67, SELL | LMNA 4444/4885POLB 2776/4885USP2 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.